Navigation Links
Emerging lymphoma and myeloma treatments focus on improving individual patient response
Date:12/12/2011

or rituximab every two months for up to two years.

After a complete assessment by both investigators and an independent radiology review, trial data revealed that treatment with GA101 resulted in higher response rates in patients compared to treatment with rituximab. The ORR for GA101 was 33.3 percent versus 44.6 percent for rituximab, and the complete remission (or unconfirmed complete remission) rate in the GA101 arm was 12.2 percent compared to 5.3 percent for rituximab.

Overall, GA101 was well tolerated by most study participants. Although patients on GA101 treatment had a higher rate of infusion reactions, which are a common complication of treatment with monoclonal antibodies, they were generally considered mild and did not result in significant differences in treatment discontinuation. A greater number of patients in the rituximab arm experienced severe adverse events during the four-week induction period (nine patients vs. five GA101 patients). Severe adverse events in GA101 patients included infusion reactions, neutropenia with fever, pleural effusion (a build-up of fluid in the lung tissue), and kidney stones. Finally, more rituximab-treated patients than GA101-treated patients discontinued therapy during the induction period.

"This is the first head-to-head trial of a novel anti-CD20 monoclonal antibody, GA101, against rituximab and we are encouraged to see a trend toward higher response rates without appreciable differences in safety," said lead author Laurie H. Sehn, MD, MPH, Clinical Associate Professor in the Division of Medical Oncology at the University of British Columbia and the British Columbia Cancer Agency, Center for Lymphoid Cancer in Vancouver, Canada. "Given the promising efficacy of this drug, definitive Phase III studies evaluating its benefit are warranted and are currently underway."

Dr. Sehn will present this study in an oral presentation on Monday, December 12, at 8:00 a.m. PST at the San Diego C
'/>"/>

Contact: Lindsey Love
llove@hematology.org
540-538-9326
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Emerging public health crisis linked to mortgage default and foreclosure
2. Emerging pharmaceutical platform may pose risks to retinal health
3. Georgia Tech researchers receive 3 NSF Emerging Frontiers awards
4. ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer
5. ATS issues report on emerging issues in HIV-associated pulmonary disease
6. Emerging drug class may enhance red blood cell production in anemic patients
7. New Society for Social Neuroscience to help guide emerging field
8. Live streaming of emerging brain science and health news
9. Emerging E. coli strain causes many antimicrobial-resistant infections in US
10. Neuxpower Selected as 2010 Emerging Technology Vendor by CRN Magazine
11. Experts explore emerging evidence linking diabetes and cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 The Little Gym of Houston ... Sunday, July 27 at Discovery Green in downtown Houston. ... Katy, Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, ... , “We’re thrilled to be attending and performing at ... who owns the Sugarland-Missouri City location. “We believe in ...
(Date:7/25/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Ibuprofen and Oxcarbazepine Tablets . , The FDA ... one lot of Oxcarbazepine Tablets, by American Health Packaging (AHP), ... used for the treatment of certain types of seizures in ... recall is that Lot #142588, Expiration Date, 01/2016 of Ibuprofen ...
(Date:7/25/2014)... Ticket Down is a reliable ... in Berkeley at California Memorial Stadium. With the post-World ... football, the organizers of the 2014 Guinness International Champions Cup ... North America. With teams representing La Liga, English Premier League, ... of the best football players from around the world to ...
(Date:7/25/2014)... 2014 On July 22, 2014, ... client and the nation’s number one provider of ... announced their partnership with TransAct Merchant Solutions’ National ... ISO/MSP of Chase Paymentech Solutions, LLC, which provides ... Companies that are members of TransAct’s National Association ...
(Date:7/25/2014)... Hastings and Hastings, a personal injury ... to personal injury claims, announces free initial consultations. Hastings ... services for those that have been injured as a ... Free initial consultation services gives clients’ greater flexibility in ... personal injury claim . It also offers clients the ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... A long-running Merck ad featured an older woman with this message: ... be?" and recommended that women ask their doctors about bone ... Merck's drug Fosamax. But this very drug, (generic name alendronate) turned ... the risk of hip fracture from 2 percent to 1 percent, ...
... the time of Chaucer were not dwarfs but only short ... was the case with women more or less, a new ... revealed. ,As part of their study, scientists researched ... upon Humber, North East Lincolnshire, and found that the average ...
... engineered adult stem cells from human umbilical cord blood to ... type 1 diabetes by allowing people to grow their own ... ,The study was conducted by a team of researchers led ... Branch at Galveston. ,As part of the study, ...
... has decided to send youths to learn meditation from Indian ... visit to the war-hit country Thursday with a trip ... the Art of Living Foundation, Iraqi Youth Minister Jasin Mohammed ... of Iraq to Bangalore to undergo the group's Youth Leadership ...
... Abdul Kalam Friday urge the nation's doctors to work for ... Post-Graduate Institute of Medical Sciences in Rohtak, Kalam called upon ... ,If each doctor showed the zeal to treat at ... lot of diseases could be taken care of. ...
... by the American Academy of Neurology finds conventionally recommended ... system Lyme disease. However, there is no compelling ... in treating symptoms that persist following standard therapy. The ... edition of Neurology, the scientific journal of the American ...
Cached Medicine News:Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 2Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 3Health News:Our Medieval Ancestors Were More or Less Similar to Us Than Previously Thought 2Health News:Art of Living Foundation to Train Iraqi Youths 2Health News:Antibiotics Highly Effective for Treating Lyme Disease 2
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems ... the Australia Capsule Endoscopy Systems market. The report provides ... and average prices (in US dollars) within market segments: ... , Capsule Endoscopes , Capsule Endoscopy Data ... The report also provides company shares and distribution shares ...
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... Powers Lake, Wisconsin , announce that ... and co-marketing agreement allowing ScriptPro to bring TCGRx ... the United States . ScriptPro is ... workflow systems to retail and ambulatory pharmacies. TCGRx ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. ... binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... the acquisition of both cultivation and dispensary medical marijuana licenses ... to the MOU, GBLX will acquire a 20% equity interest ... proprietary GrowBLOX TM growing chambers, as well as all ...
Breaking Medicine Technology:Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
... 03, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today ... Phase 2 trial of GVAX,immunotherapy for prostate ... in 80 patients with metastatic,hormone-refractory prostate cancer ... received the dose that is comparable to ...
Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Bausch & Lomb PreserVision® Soft Gel ... clinically proven Bausch & Lomb PreserVision® AREDS ... mg of FloraGlo Lutein., Lutein is a ... such as spinach. Lutein is highly concentrated ...
... a scientifically advanced multinutrient that ... and full body health. It ... including a diverse array of ... lycopene and OptiBerry and important ...
Medicine Products: